stockportfolio.pro
Stocks / ARWR vs HSIC
ARWR vs HSIC
Arrowhead Pharmaceuticals, Inc. and Henry Schein, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Henry Schein, Inc. (HSIC) | |
|---|---|---|
| Market cap | $10.0B | $9.2B |
| Revenue (latest FY) | $829.45M | $13.18B |
| Net income (latest FY) | $-1.63M | $398.00M |
| Revenue growth (5y CAGR) | 56.6% | 5.4% |
| Net margin | -0.2% | 3.0% |
| Return on equity | -0.3% | 12.3% |
| P/E ratio | — | 24.5 |
| Dividend yield | — | — |
| Profitable years (of last 10) | 1 | 10 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open ARWR — free Open HSIC — freeFrequently asked questions
Which is bigger, ARWR or HSIC?
Arrowhead Pharmaceuticals, Inc. is larger by market capitalization — $10.0B versus $9.2B.
Which grows faster, ARWR or HSIC?
Over the last five fiscal years, Arrowhead Pharmaceuticals, Inc. grew revenue faster — 56.6%/yr versus 5.4%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.